Genzyme has appointed David Meeker to the newly created position of chief operating officer. Meeker began working at Genzyme in 1994 and most recently held the position of president of the global genetic diseases business.
Eric Richman has been promoted to the position of president and chief operating officer at PharmAthene. Richman joined PharmAthene in 2003 and most recently worked as senior vice president (SVP), business development and strategic planning.
PharmAthene made two other promotions, naming Francesca Cook as SVP, policy and government affairs and Valerie Riddle as SVP, medical director. Richman, Cook and Riddle all joined PharmAthene in October 2003.
Cadence Pharmaceuticals has appointed Michael Eagle to the company’s board of directors. Eagle worked as VP of manufacturing at Eli Lilly for seven years and serves on the boards of directors of Somaxon Pharmaceuticals, Micrus Endovascular and Cardio Polymers.
George Abercrombie has joined the board at Ziopharm Oncology. Abercrombie has 30 years experience in the pharma industry, most recently as president and CEO of Hoffman-La Roche. Before joining Roche in 2001 Abercrombie worked at Glaxo Wellcome and Merck & Co.
Intrexon has bolstered its protein production division by appointing Richard Waldron as the group’s chief financial officer and Stephen Worsley as its VP, business development.
Waldron has previously worked at GeneMedicine and SciClone Pharmaceuticals. Worsley’s experience includes time working for Abgenix and Zosano Pharmaceutical.
John Alam has joined Inhibitex as senior medical advisor. Alam was formerly EVP, medicines development and chief medical officer at Vertex Pharmaceuticals.